Vegzelma Injection, Solution
Product Images NDC 72606-012

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Vegzelma (NDC 72606-012). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Celltrion Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Vegzelma 01)

A survival curve chart comparing the proportion of patients surviving over a duration of up to 30 months. Two groups are shown: IFL plus placebo (gray line) and IFL plus bevacizumab (black line). The chart displays the number of patients at risk at different time points for each group.*

FDA Label Image

Figure 2 (Vegzelma 02)

A survival curve chart depicting the proportion of patients surviving over a 48-month study period. The chart compares two randomized treatment groups: chemotherapy alone (dashed line) and chemotherapy plus bevacizumab (solid line). The number of patients at risk at various time points is provided below the x-axis.*

FDA Label Image

Figure 3 (Vegzelma 03)

A survival curve graph showing the proportion of patients surviving over a duration of up to 50 months. Two lines represent patient groups: one receiving PC treatment alone (n=444) and another receiving PC plus bevacizumab (n=434). The x-axis displays survival duration in months, and the y-axis shows the proportion surviving. A table below the graph lists the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 4 (Vegzelma 04)

A Kaplan-Meier curve chart showing progression-free survival over 24 months comparing two groups: placebo plus IFN-alfa and bevacizumab plus IFN-alfa. The y-axis represents the proportion progression free, and the x-axis represents time in months. The chart includes patient numbers at risk at various time points for both groups.*

FDA Label Image

Figure 5 (Vegzelma 05)

A Kaplan-Meier survival curve comparing overall survival proportions over 42 months between two groups: one receiving chemotherapy alone and the other receiving chemotherapy plus bevacizumab. The graph shows distinct survival trends for each group with a legend and number at risk table below the x-axis, which measures overall survival in months, while the y-axis measures the proportion of overall survival.*

FDA Label Image

Figure 6 (Vegzelma 06)

A Kaplan-Meier survival curve chart showing the proportion of progression-free survival over time in months for two groups: CT (chemotherapy) and CT+BV (chemotherapy plus bevacizumab). The y-axis represents the proportion of progression-free patients, while the x-axis shows the duration in months up to 24. The chart includes a risk table indicating the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 7 (Vegzelma 07)

A Kaplan-Meier curve chart showing the proportion of progression-free survival over time in months. The chart compares two groups: CT (chemotherapy) with 182 patients and CT+BV (chemotherapy plus bevacizumab) with 179 patients. The y-axis represents the proportion of progression-free patients, and the x-axis represents the duration of progression-free survival in months, with additional numbers at risk listed below the x-axis.*

FDA Label Image

Figure 8 (Vegzelma 08)

A Kaplan-Meier survival curve chart depicting proportion progression-free over time (months) since randomization. Two groups are compared: CG+Pl (dashed gray line) and CG+Bv (solid black line), showing progression-free rates over approximately 30 months. Patient numbers at various time points are listed below the x-axis.*

FDA Label Image

Figure 9 (Vegzelma 09)

A survival curve graph showing proportion surviving over study months for two treatment groups: Crb+Pac (solid line) and Crb+Pac+Bev (dashed line). The x-axis represents study months from 0 to 84, and the y-axis shows proportion surviving from 0 to 1. A table below the graph lists numbers at risk for each group at various time points.*

FDA Label Image

Principal Display Panel (4 mL Vial Carton)

Packaging label for Vegzelma (bevacizumab-adcd) injection, 100 mg/4 mL (25 mg/mL) for intravenous infusion after dilution. The label includes dosage storage instructions, manufacturer CELLTRION USA, Inc., and a barcode. It describes a single-dose vial and advises discarding unused portions.*

FDA Label Image

Principal Display Panel (16 mL Vial Carton)

Packaging label for Vegzelma (bevacizumab-adcd) Injection 400 mg/16 mL (25 mg/mL) by CELLTRION USA, Inc. The label details it is for intravenous infusion after dilution, supplied as a single-dose vial with storage instructions to refrigerate at 2°C to 8°C. It includes dosage form, active ingredient strength, manufacturer and distributor information, and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.